Cartalax10 mg per vial
- Formula
- C12H19N3O8
- Molar mass
- 333.3 g/mol
- CAS number
- 85806-95-7
- Amino acids
- 3
- Sequence
- Ala-Glu-Asp
- Class
- Synthetic tripeptide from the Khavinson bioregulator series, sold as a cartilage and bone bioregulator
Cartalax / BPC-157 / TB-500 Blend
This blend adds the Khavinson tripeptide Cartalax to the BPC-157 / TB-500 repair pair in one vial, here at 10/10/10 mg.
Blend calculations, explained
A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.
Per-component concentration math
Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.
Vial strength is not a target amount
Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.
How to read the dosing on this page
Blend-level rows
Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.
Component rows
Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.
One draw, every component
The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.
Molecular profile of each component
Cartalax / BPC-157 / TB-500 Blend is 3 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.
BPC-15710 mg per vial
- Formula
- C62H98N16O22
- Molar mass
- 1,419.5 g/mol
- CAS number
- 137525-51-0
- Amino acids
- 15
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Class
- Synthetic pentadecapeptide, described as a fragment of a human gastric juice protein
TB-500 / TB-410 mg per vial
- Formula
- C38H68N10O14
- Molar mass
- 889 g/mol
- CAS number
- 885340-08-9
- Amino acids
- 7
- Sequence
- Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH
- Class
- Synthetic N-acetylated heptapeptide covering residues 17-23 of human thymosin beta-4 (the actin-binding motif); PubChem titles the record by its UNII. It is not the full 43-residue thymosin beta-4 (timbetasin, 4963 g/mol), which many vendors also sell under the TB-500 name
Reported protocols for Cartalax / BPC-157 / TB-500 Blend
What published studies and recent community write-ups report about amounts, timing and course length. 1 preclinical row, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical1 row | |||||
| Preclinical: BPC-157 + TB-500 pair only (no Cartalax arm), rat Achilles tendon repair32 male Sprague-Dawley rats after Achilles tendon transection and repair, 8 per group (vehicle, BPC-157, TB-500, both) | BPC-157 10 mcg/kg/day plus TB-500 60 mcg/kg/day; Cartalax was not studied | Once daily | Intraperitoneal injection | 30 days after surgery, reported as four weeksNot applicable | Joint Diseases and Related Surgery2026 |
| Included because it is the only animal work on any part of this combination; it covers two of the three components and says nothing about Cartalax. TB-500 alone gave the only significant gain in load to failure, the pair improved one histology score without beating either single agent, and the authors suggest the two peptides converge on shared pathways. Four tendons per group went to histology and each compound was tested at a single dose. | |||||
Sources for this section (7)
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats (PubMed record, PMID 42542926)
Plus 5 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Reported protocols by component
What sources report for each peptide on its own. In Cartalax / BPC-157 / TB-500 Blend the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.
Cartalax
- Community-reportedKhavinson-style injectable course
- Reported amount
- 200-400 mcg
- Frequency
- Once daily, morning, fasted
- Route
- Subcutaneous
- Course
- 10-20 days
- PreclinicalChondrogenic differentiation of aging human mesenchymal stem cells
- Reported amount
- 200 ng/mL in the culture medium (the whole cartilage polypeptide complex needed 2,000 ng/mL)
- Frequency
- Added to the culture medium
- Route
- In vitro
- Course
- Length of the culture experiment, not stated in the abstract
- PreclinicalGene expression in aging bone marrow stem cell cultures
- Reported amount
- Nanomolar concentrations (the abstract reports the 10^-9 mol/L range without an exact figure)
- Frequency
- Added to the culture medium
- Route
- In vitro
- Course
- Duration of the aging culture experiment
BPC-157
- ClinicalIntra-articular knee injection, retrospective chart review
- Reported amount
- 4 mg (2 mL of a 2,000 mcg/mL solution); 2-4 mg when combined with TB4
- Frequency
- Single injection
- Route
- Intra-articular
- Course
- One procedure, with phone follow-up 6-12 months later
- Community-reportedAcute soft-tissue injury cycle
- Reported amount
- 250-500 mcg per day
- Frequency
- Once or twice daily
- Route
- Subcutaneous, as close to the injury as practical
- Course
- 4-6 weeks
- PreclinicalPreclinical rodent tendon and muscle models
- Reported amount
- 10 mcg/kg or 10 ng/kg (10 pg/kg also tested)
- Frequency
- Once daily
- Route
- Intraperitoneal injection in saline; intragastric and drinking-water dosing also used
- Course
- Typically 14-21 days, through the end of the healing model
TB-500 / TB-4
- ClinicalPhase 1 intravenous thymosin beta-4 in healthy volunteers (full-length protein)
- Reported amount
- 42, 140, 420 or 1,260 mg
- Frequency
- Single dose, then the same dose once daily for 14 days
- Route
- Intravenous
- Course
- 14 days
- Community-reportedCommunity loading and maintenance protocol
- Reported amount
- 2-2.5 mg
- Frequency
- Twice weekly for 4-6 weeks (loading), then once weekly (maintenance)
- Route
- Subcutaneous from a 10 mg vial reconstituted in 2 mL (5 mg/mL; 0.4-0.5 mL or 40-50 units per dose)
- Course
- 4-6 weeks of loading plus 6-8 optional weeks of maintenance
- PreclinicalPreclinical rat full-thickness wound model (full-length protein)
- Reported amount
- 5 mcg in 50 mcL topically per wound; 60 mcg in 300 mcL intraperitoneally
- Frequency
- Topical at wounding and again at 48 hours; intraperitoneal at wounding and every other day
- Route
- Topical or intraperitoneal
- Course
- 7 days
What is available now
These fields come from the existing picker, blend catalog and observed presentation data. They are identity and availability context, not evidence of effectiveness.
This blend adds the Khavinson tripeptide Cartalax to the BPC-157 / TB-500 repair pair in one vial, here at 10/10/10 mg. Vendors sell it as a joint and cartilage version of the Wolverine stack: one vendor's Wolverine+ carries 10 mg Cartalax with 5 mg each of BPC-157 and TB-500, while two others (as Wolverine 2.0 and RENU) sell the 10/10/10 vial this page describes. No study has tested the three together, no published study has dosed Cartalax in a living animal or person, and the only combination data is a 2026 rat tendon study of the BPC-157 and TB-500 pair that found no additive benefit, so the evidence lives on the component pages.
- 1
Entry type
Fixed-ratio blend reference
Kept separate from single-peptide evidence and terminology.
- 2
Evidence status
Structured review queued
No evidence level is assigned until references and study models are reviewed.
- 3
Calculator access
Advanced Blend workspace
Calculator access performs arithmetic; it does not establish an amount or protocol.
- 4
Market presentation data
No reviewed observation on file
The vial label remains the authoritative source for any calculation.
Recorded blend variants
Each number is the vial amount for that component. It is not a per-draw amount.
- Cartalax
- 10 mg
- BPC-157
- 10 mg
- TB-500 / TB-4
- 10 mg
Sources
5 curated references, each with its journal, year and study model, plus 5 community resources reported but not linked.
- Ala-Glu-Asp, Cartalax (PubChem CID 87815447)
- Bpc-157 (PubChem CID 9941957)
- TB-500 (PubChem CID 62707662)
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats (PubMed record, PMID 42542926)